Shree Ganesh Remedies Ltd — Important, 15-05-2026: Company Update

Shree Ganesh Remedies announced its Q4 and FY26 audited financial results. For Q4, revenue grew 36% YoY to 33.20 Cr, EBITDA increased 15% to 11.37 Cr, but PAT declined 5% to 6.27 Cr. For the full year, revenue rose 1% to 109.29 Cr, while EBITDA fell 11% to 35.02 Cr and PAT was down 23% to 17.77 Cr. The company views FY26 as a consolidation year, building stronger foundations. It reported strong progress on CRAMS projects with pilot trials completed, moving to commercial phase. Block 7 expansion is on track for Q2FY27 commercial production, positioning the company for future growth despite challenging market conditions.